-
Mashup Score: 1Extending efficacy for CAR T-cell therapies - 7 month(s) ago
Fred Hutchinson Cancer Center immunotherapy researcher Dr. Shivani Srivastava received an NCI MERIT Award to study T-cell reservoirs to help improve CAR T-cell therapies against solid tumors.
Source: www.fredhutch.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Extending efficacy for CAR T-cell therapies - 7 month(s) ago
Fred Hutchinson Cancer Center immunotherapy researcher Dr. Shivani Srivastava received an NCI MERIT Award to study T-cell reservoirs to help improve CAR T-cell therapies against solid tumors.
Source: www.fredhutch.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr. Shivani Srivastava (@sriv4000) has received a MERIT Award from @theNCI to investigate how to improve engineered #CARTcell cancer #immunotherapies against solid tumors through reservoirs of self-renewing immune cells. Read more👇 https://t.co/aAtnI3shCc
-
-
Mashup Score: 0The impact of bridging therapy on the outcomes of patients with R/R myeloma treated with ide-cel - 7 month(s) ago
Larry Anderson, MD, PhD, UT Southwestern Medical Center, Dallas, TX, discusses a real-world study evaluating the impact of various forms of bridging therapy (BT) on the outcomes of patients with relapsed/refractory (R/R) multiple myeloma being treated with idecabtagene vicleucel (ide-cel). Dr Anderson highlights the impact of these forms of BT on progression-free and overall survival (PFS; OS), and comments on the importance of bringing CAR-T therapy into earlier lines. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
It was great to speak w/ @ldandersonjr at #IMS23, who discussed a study evaluating the impact of various forms of bridging therapy on the outcomes of patients with R/R MM treated with ide-cel: 👉 https://t.co/0nPcvhZWti #MMsm #CARTcell @Myeloma_Society
-
-
Mashup Score: 1
Tanya Siddiqi, MD, City of Hope, Duarte, CA, summarizes outcomes of the Phase I/II TRANSCEND-CLL-004 study (NCT03331198), which is investigating the safety and efficacy of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). This study met its primary endpoint, and Dr Siddiqi talks on the clinical benefit of this CAR-T product in this patient population. To conclude, Dr Siddiqi highlights the curative potential of this therapy and comments on the possibility of using CAR-T cells earlier in the treatment of CLL or in combination with other agents. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out our recent interview w/ Tanya Siddiqi of @cityofhope, who summarizes outcomes of the TRANSCEND-CLL-004 study, which is evaluating liso-cel in R/R CLL: 👉 https://t.co/910pC7GWEv #LeuSM #CLLsm #CARTcell #ImmunoOnc @SocietyofHemOnc
-
-
Mashup Score: 0IMS 2023 | VJHemOnc - 7 month(s) ago
The 20th International Myeloma Society (IMS) Annual Meeting was held in Athens, Greece, from 27-30 September, 2023. This meeting focused on the latest basic, preclinical, and clinical advances in the field of multiple myeloma. The 20th International Myeloma Society (IMS) Annual Meeting was held in Athens, Greece, from 27-30 September, 2023. This meeting focused on the latest basic, preclinical, and clinical advances in the field of multiple
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Missed out on #IMS23? Don’t worry! We’ve got all you need - check out our expert interviews here: 👉 https://t.co/0ZcFKvFI09 #MMsm #HemOnc #ImmunoOnc #CARTcell https://t.co/PJ3s43oTc0
-
-
Mashup Score: 2La SEHH presenta las Guías en Cardio-Oncología 2022 para hematólogos - 7 month(s) ago
La Sociedad Española de Hematología y Hemoterapia (SEHH) ha presentado las Guías en Cardio-Oncología 2022…
Source: www.infosalus.comCategories: Hem/Oncs, Latest HeadlinesTweet-
La @sehh_es presenta las Guías en Cardio-Oncología 2022 para hematólogos en el Aula Magna de la @Hospital_FJD #CardioOnc @TeresaLpezFdez1 #lymsm #mmsm #leusm #bmtsm #CARTcell https://t.co/VmJ8kjG2sm
-
-
Mashup Score: 4A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development - 7 month(s) ago
YTB323, a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, retains T-cell stemness after a manufacturing process time of less than 2 days and demonstrates clinical antitumor activity at significantly lower doses than traditionally manufactured CAR T cells.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI from the latest issue— A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-Cell Stemness Shows Enhanced #CARTCell Efficacy in Preclinical and Early Clinical Development, by @mike_dickinson1 et al. https://t.co/Y0Drql5yzF @PeterMacCC #Immunotherapy https://t.co/rFdQdmX1dR
-
-
Mashup Score: 0Regina Myers, MD[slides]-CART Cell-Relapse and Antigen Modulation - 7 month(s) ago
Regina Myers, MD, MSCE, is an instructor in the Cancer Center at Children’s Hospital of Philadelphia. Regina Myers, MD expresses gratitude for the audience’s presence and thanks the event organizers for the invitation. They introduce themselves as a pediatric oncologist speaking at an adult conference, focusing on p…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🔬 Exciting CAR T cell strategies revealed! Discover innovative ways to combat relapse & antigen challenges in pediatric & adult patients. Thank you @reginamyersmd @_MDEducation @Ryan_fitzpatric.#CARTCell [slides][video]https://t.co/MRNP6LRMKC https://t.co/8E7sDNAZ2H
-
-
Mashup Score: 1Expertos reclaman actualizar el `Plan de Abordaje de Terapias Avanzadas en el Sistema Nacional de Salud´ - 7 month(s) ago
Profesionales sanitarios y representantes políticos se reúnen en el marco del Día Mundial del Linfoma y el Mes de Concienciación de los Cánceres de la Sangre para debatir sobre cómo continuar con el éxito de la implantación del Plan de Terapias Avanzadas en nuestro país y sobre cómo dar …
Source: www.immedicohospitalario.esCategories: Hem/Oncs, Latest HeadlinesTweet-
@IMMedicoHosp: “Expertos reclaman actualizar el `Plan de Abordaje de Terapias Avanzadas en el Sistema Nacional de Salud´” #CARTcell #lymsm #hematología https://t.co/xt1iJldnn8..
-
-
Mashup Score: 0Updates on the use of CAR-T therapy in MCL - 7 month(s) ago
Tycel Phillips, MD, City of Hope, Duarte, CA, shares some insights into the use of CAR-T therapy in mantle cell lymphoma (MCL), highlighting the use of brexucabtagene autoleucel (brexu-cel) as a mainstay treatment in recent years. Dr Phillips comments on the rates of immune effector cell-associated neurotoxicity syndrome (ICANS) observed with the use of this agent, as well as relapse rates. Dr Phillips also talks on lisocabtagene maraleucel (liso-cel), which has not yet been investigated in patients with MCL, but has demonstrated a similar efficacy to brexu-cel with a significantly reduced incidence of ICANS. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We caught up with Tycel Phillips (@LymphClinician; @cityofhope), who shared some updates on CAR-T therapy in MCL, highlighting the use of brexu-cel as a mainstay treatment: 🎥 https://t.co/V8S71ArUdg #SOHO23 #LymSM #HemOnc #ImmunoOnc #CARTcell
-
Dr. Shivani Srivastava (@sriv4000) has received a MERIT Award from @theNCI to investigate how to improve engineered #CARTcell cancer #immunotherapies against solid tumors through reservoirs of self-renewing immune cells. Read more👇 https://t.co/aAtnI3sPrK